Stocks struggle as Trump slaps new tariffs, Fed cut bets unwind

U.S. President Donald Trump announced new tariffs, including a 100% duty on imported branded drugs and duties on heavy-duty trucks and kitchen cabinets, effective October 1, which contributed to a shaky start for Asian equities and a 1.4% decline in Japan’s pharmaceutical index. This tariff news, coupled with stronger-than-expected U.S. economic data, has led traders to significantly pare back expectations for aggressive Federal Reserve rate cuts, now pricing in only about 39 basis points by December, consequently bolstering the dollar.

Analysis

A dual shock from aggressive U.S. trade policy and shifting monetary policy expectations has created a cautious-to-negative environment for risk assets, particularly in Asia. The announcement of new U.S. tariffs, most notably a 100% duty on imported branded drugs and a 25% tariff on heavy-duty trucks effective October 1, directly impacted market sentiment. This was evidenced by a 1.4% slide in Japan's Topix pharmaceutical index and a more than 3% decline in shares of Australian biotech firm CSL. Concurrently, stronger-than-expected U.S. economic data, which Wells Fargo economists characterized as "undeniably resilient," has led traders to scale back expectations for Federal Reserve easing. The market is now pricing in approximately 39 basis points of rate cuts by December, down from over 40 bps, a hawkish shift that has provided support for the U.S. dollar, pushing it towards the 150 yen level. This dynamic places upcoming inflation data, such as the PCE report, in sharp focus as a key determinant for the future path of interest rates. Secondary developments include rising oil prices amid geopolitical discussions between the U.S. and Turkey regarding Russian oil purchases and potential sanctions relief.

Key Decisions for Investors

• Investors with exposure to the pharmaceutical and biotech sectors should immediately assess the vulnerability of their holdings to the new 100% U.S. tariff on imported branded drugs, as companies with significant U.S. import operations face severe margin pressure.
• Given that markets are repricing for a less dovish Federal Reserve due to strong economic data, it is prudent to review positions sensitive to falling interest rates and consider that the U.S. dollar may exhibit continued strength.
• The combination of sudden tariff announcements and evolving Fed policy outlook suggests a period of heightened cross-asset volatility; therefore, reviewing portfolio hedges and reducing exposure to high-beta risk assets may be warranted.
• Monitor upcoming U.S. PCE data closely, as it will be a critical catalyst in either confirming the hawkish shift in rate expectations or reigniting hopes for more aggressive Fed cuts.